Your English writing platform
Discover LudwigExact(2)
Fifteen non-demented patients with early PD (stable responders treated by l-dopa) were compared to 28 healthy age and education matched controls.
In optimal and stable responders, a policy of intermittent imatinib treatment is feasible, is successful in about 50% of patients and is safe, as all the patients who relapsed could be brought back to optimal response.
Similar(58)
We dichotomised the observed changes and our dependent variable contained 0 for patients who progressed or remained stable (non-responders) in their BML scores and 1 for patients responding positively (responders) [ 37].
For this analysis, we dichotomised patients into non-responders (progressive disease) and responders (stable disease or remission).
This observation likely accounts for the decreasing (improving) NNTs for active treatment over time despite the generally stable percentages of responders.
Among the nine patients available for response evaluation (RECIST 1.1), three patients had responded (partial response) and six patients were non-responders (stable disease).
Non-responders (stable disease in 15 patients; progression disease in 22 patients) had a median TTP of 13 weeks (range 4 65 weeks).
14, 15 Utilities representing health-related quality of life for each state included in the Markov model (stable disease: 0.65; responder: 0.81; progression: 0.45; death: 0) were drawn from a pooled analysis of MBC utility weights.
Change in [C]thymidine incorporation was more marked in the responder but remained stable in the non-responding case[ 70 ].
Mutations in FBXW7 were identified in six samples (9 %): five in the non-responders and one in the stable disease subgroup of the responders.
Non-responders (= PD at 1-month follow-up, n = 10) had a significant increase of Ang-2 and HGF at 3 and 7 days post treatment compared to responders (= stable disease or better, n = 32), who showed little to no changes in plasma levels (respectively p = 0.01 and p = 0.007).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com